despite polycystic ovary syndrome (pcos) is a very prevalent disorder among women of reproductive age, there is widespread agreement that until now, no pharmacological options are available to tackle the entire spectrum of clinical manifestations encountered in the clinical practice. obesity and insulin resistance, which commonly characterized this syndrome, prompted the design of studies investigating the effects of glucagon-like peptide 1 (glp-1) receptor agonists (glp-1ra) in pcos. indeed, a very impressive number of randomized controlled clinical trials (rcts) and systematic reviews provided robust evidence on the effectiveness of glp-1ra in pcos as a new, appealing approach, producing both satisfactory and permanent weight loss, and improvement of insulin resistance at the same time. however, most of the subjects included in the rcts are pcos patients with obesity/overweight, whereas a portion of pcos women, which can even reach 50%, might present a lean phenotype. moreover, some benefits on clinical and metabolic features of pcos may not have fully emerged due to the low or medium doses employed in the vast majority of the current studies. thus, pitfalls in the methodology of these studies have led sometimes to misleading results. in addition, some aspects of glp-1 beyond weight loss, such as preclinical evidence on glp-1 effects in directly modulating the hypothalamus–pituitary–gonadal axis, or the effects of glp-1ra on clinical and biochemical expression of hyperandrogenism, still deserve a greater insight, especially in light of a possible therapeutic use in pcos women independently of obesity. aim of this review is to further unravel the possible role of glp-1 in pcos pathogenesis, tempting to provide additional supports to the rationale of treatment with glp-1ra in the management of pcos also independent of weight loss. for this purpose, the outcomes of rcts investigating in pcos the anthropometric and metabolic changes have been treated separately to better underpin the effects of glp-1 ra, in particular liraglutide, beyond weight loss.
glucagon-like peptide-1 (glp-1) analogues have emerged as promising therapeutic agentsfor the treatment of type 2 diabetes. recent studies have suggested a potential role of glp-1in reproductive functions, offering new avenues for fertility treatment. this paper aims toreview the current understanding of glp-1 analogues to human reproduction, focusing ontheir potential application in fertility treatment, and discussing the molecular mechanismsand signalling pathways involved. further, we highlight the challenges and future directionsin the application of glp-1 analogues for fertility treatment.
https://cdn.prod.website-files.com/623de5fee0c46d7bf3a5ff45/658c8d87a7939e4251bd409f_ozempic%20for%20pcos.avif
glp-1 receptor agonist use was associated with variable weight loss outcomes and reproductive and metabolic benefits among individuals with pcos.
background polycystic ovary syndrome (pcos) is a common endocrine disorder associated with metabolic and hormonal abnormalities. this study aimed to evaluate the comparative efficacy of pharmacological interventions on these outcomes. methods we conducted a systematic review and network meta-analysis of randomized controlled trials (rcts) assessing pharmacological treatments for pcos. searches in pubmed, medline, embase, and web of science were conducted up to october 20, 2023. eligible studies were rcts with at least 12 weeks of follow-up and outcomes including body weight (bw), body mass index (bmi), waist circumference (wc), testosterone, sex hormone-binding globulin (shbg), lipid profiles, homa-ir, fasting blood glucose (fbg), and fasting insulin (fins). results twenty-nine rcts with 1476 participants were included. the combination of standard therapy with glp-1 receptor agonists significantly reduced bw (md= -3.44; 95% ci= -6.20 to -0.67), bmi (md= -2.05; 95% ci= -3.55 to -0.55), and wc (md= -4.39; 95% ci= -6.75 to -2.02) compared to standard therapy alone. orlistat significantly lowered testosterone (smd= -2.16; 95% ci= -3.84 to -0.48) and increased hdl-c levels (smd = 0.90; 95% ci = 0.02 to 1.79) compared to placebo. the combination therapy also reduced homa-ir (md= -1.29; 95% ci= -2.38 to -0.21) and fbg (smd= -1.80; 95% ci= -3.04 to -0.55) compared to placebo. conclusion combining standard therapy with glp-1 receptor agonists offers superior efficacy in improving metabolic and hormonal outcomes in women with pcos. orlistat effectively reduces androgen levels. these findings support the use of combination pharmacotherapy for comprehensive management of pcos.
what is the role of glucagon-like peptide-1 (glp-1) analogs in polycystic ovary syndrome (pcos)?
glp-1 receptor agonists, such as liraglutide, can benefit patients with polycystic ovary syndrome (pcos), particularly those with obesity, by promoting weigh...
https://cdn.prod.website-files.com/60e33881a9643382c407b823/6810d66db4eae13c6d93038a_istock-1605492350_copy.jpeg
the research is early-stage, but doctors are hopeful about the hormonal upsides of these weight-loss drugs.
polycystic ovary syndrome (pcos) is a common endocrine disorder affecting millions of women worldwide. learn more about glp-1s and pcos
the effects of glucagon-like peptide-1 receptor agonists on gut microbiota with metabolic parameters including body weight and the hormone profile in pcos.
investigating glp-1 ras reveals their impact on women's health, addressing metabolic disorders, reproductive health, and cardiovascular risks during menopause.
september is pcos awareness month. discover how glp-1 peptide injections, hormone replacement therapy (hrt), and targeted hair treatments can help manage pcos symptoms like weight gain, irregular periods, and hair issues. consult with our experts to tailor a treatment plan and take control of your health.
obesity drugs like wegovy are proving useful in many diseases. polycystic ovary syndrome, a chronic condition that can cause infertility, may be one.
researchers got a surprise when they discovered people taking glp-1s were losing weight and reporting feeling fuller. the surprises keep coming – both welcome and worrisome.
purpose this study was aimed to assess the effectiveness of glucagon-like peptide 1 receptor agonists on pregnancy rate, menses, anthropometric and hormonal parameters in pcos patients. methods we conducted searches of the published literature in pubmed, embase, cochrane library, web of science up to september 2022. data from randomized controlled trials were obtained to assess the effects of glp1ras in pcos women. weighted mean difference, standardized mean difference, and risks ratio were employed for effect size estimation using a random-effects model. results a total of 840 patients with 469 individuals in glp1ras group and 371 individuals in control group from 11 rcts were included. glp1ras usage was associated with an improvement in natural pregnancy rate (rr: 1.72, 95% ci 1.22 to 2.43, p = 0.002, i2 = 0%) and menstrual regularity (smd: 1.72, 95% ci 0.60 to 2.85, p < 0.001, i2 = 95.6%). there were no statistically significant differences in total pregnancy rate, ivf pregnancy rate between two groups, but total pr elevated in a short time after glp1ras as shown in subgroup analysis. randomization to glp1ras treatment was associated with great improvement in homa-ir, bmi, wc, shbg and a slight reduction in tt compared to control group. a decrease in tbf was seen in european population. glp1ras monotherapy was not superior to metformin when it came to ft, dheas, fai. conclusions prescription of glp1ras improves natural pregnancy rate, menstrual cyclicity and insulin sensitivity, anthropometrics, hormonal indexes in pcos women.
explore how glp-1 medications may impact fertility and menstrual cycles in women with pcos. learn about recent studies, metabolic benefits, and their potential role in managing pcos-related infertility.
enjoy the videos and music that you love, upload original content and share it all with friends, family and the world on youtube.
polycystic ovary syndrome (pcos) is a common endocrine disorder, with a prevalence of 5% to 15% in premenopausal women. patients with pcos presents as abnormal menstruation, ovulation disorders and/or hyperandrogenemia, and often accompanied by insulin resistance and other metabolic abnormalities....
metabolic complications are common in patients suffering pcos, including obesity, insulin resistance and type-2 diabetes. here the authors show the efficacy of glp1-based multi-agonists, and superiority of glp1/e, for managing metabolic complications of pcos in preclinical models, with improvement also of some reproductive traits.
unlock the power of glp1 agonists for pcos! dive into our blog for must-know insights before taking the leap. your path to pcos management starts here
polycystic ovary syndrome (pcos) is the most prevalent endocrinopathy in women of reproductive age. this condition is characterized by hyperandrogenism and either oligo- or anovulation. pcos patients often present comorbidities such as obesity, insulin resistance, impaired glucose metabolism, dyslip …
think of the eternal question about the chicken and the egg. the relationship between glp-1s and pcos isn’t all that different. let's unpack it.
https://cdn.prod.website-files.com/61e870c3b76ffad48d417ae7/6203133d75aa09c63149f0ea_skinco%20open%20graph.jpg
polycystic ovary syndrome (pcos) affects 6-10% of women and related metabolic complications include insulin resistance (ir), diabetes and nonalcoholic fatty liver disease (nafld), which all present in...
polycystic ovary syndrome (pcos) poses a multifaceted challenge, affecting women through genetic susceptibility, obesity, and insulin resistance. this narrative review explores the potential therapeutic role of glucagon-like peptide-1 receptor agonists (glp-1 ras) in pcos treatment, with a focus on weight loss and associated metabolic changes. the off-label use of glp-1 ras in this population helps to treat comorbid obesity. by thoroughly examining pcos diagnostic criteria, current treatments, and clinical trial outcomes involving glp-1 ras, this research reveals encouraging results. however, concerns about the long-term safety of glp-1 ras, including serious adverse events, warrant further investigation. while glp-1 ras hold promise for treating obesity in pcos, safety issues may limit their utility.
discover how glp-1 receptor agonists like semiglutide and wegovy offer hope for weight loss, pcos, and infertility. learn more about your options.
enjoy the videos and music that you love, upload original content and share it all with friends, family and the world on youtube.
popular diabetes and weight loss drugs may also help treat conditions including pcos, addiction, alzheimer’s, but the science has yet to catch up with lived experiences.
this meta-analysis aimed to evaluate the efficacy and safety of glucagon-like peptide-1 receptor agonists (glp-1ras) when compared to metformin and placebo in the management of body weight, glucose homeostasis and hormone levels in women polycystic ovary syndrome (pcos). a systematic search of “pubmed”, “embase”, “cochrane library”, “web of science” and “google scholar” was conducted up to october 2024 for randomized controlled trials involving adult women with pcos treated with glp-1ras compared to metformin or placebo. the primary outcomes were changes in body mass index (bmi), body weight, waist circumference (wc), waist-to-hip ratio (whr) and abdominal girth (ag). secondary outcomes included glucose homeostasis (fasting glucose, fasting insulin, ogtt results and homa-ir), hormone levels (dheas, shbg, total and free testosterone and fai), lipid profiles (total cholesterol, hdl, ldl and triglycerides) and safety. glp-1ras significantly reduced bmi, body weight, wc, whr and ag (p < 0.0001 in all cases). for glucose homeostasis, glp-1ras significantly reduced fasting insulin, glucose level at 2 h after ogtt, and homa-ir. there was also a reduction in hdl. all the other parameters measured were unchanged. in addition, glp-1ras increased nausea (p = 0.02), vomiting (0.04) and dizziness (0.03). glp-1ras effectively reduced body weight, bmi and insulin resistance in patients with pcos, although they were accompanied by nausea, vomiting and dizziness. further studies are needed to explore their long-term effects on glucose homeostasis and lipid profiles.
background: withdrawal of semaglutide is frequently followed by weight regain due to compensatory biological changes that prevent the maintenance of long-ter...
now that you have the pens in your fridge, you may be wondering how or what you should eat while taking glp medications. here’s what to know.
the diabetes rx can help with a number of symptoms